Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: Virus fitness in the absence and in the presence of drug

Journal of Virology

Volumn 74, Issue 18, 2000, Pages 8524-8531

  Mammano, F ^a   Trouplin, V ^a   Zennou, V ^a   Clavel, F ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRUS PROTEIN;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; DRUG TISSUE LEVEL; GENETIC SELECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS INFECTIVITY; VIRUS MUTATION;

AMINO ACID SUBSTITUTION; CELL LINE; DRUG RESISTANCE, MICROBIAL; EVOLUTION, MOLECULAR; GENE PRODUCTS, GAG; HELA CELLS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MUTATION, MISSENSE; RITONAVIR; SAQUINAVIR;

EID: 0033863985     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.18.8524-8531.2000     Document Type: Article

References (52)

1. An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection.
2. Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1-infected patients with and without AiDs dementia complex.
3. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within Gag/Pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
4. Resistance to human immunodeficiency virus type 1 protease inhibitors.
5. Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug.
6. Rational approaches to resistance: using saquinavir.
7. Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity.
8. HIV-1 reverse transcription: a termination step at the center of the genome.
9. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor.
10. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.
11. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors.
12. Human immunodeficiency virus protease - A target for AIDS therapy.
13. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans.
14. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team.
15. Population dynamics in the evolution of RNA viruses.
16. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors.
17. Inhibition of human i mmunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors.
18. Structure-based design of symmetric inhibitors of HIV-1 protease.
19. Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease.
20. The not-so-great escape.
21. A sensitive method for the detection of β-galactosidase in transfected mammalian cells.
22. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.
23. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure.
24. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
25. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens.
26. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs.
27. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor.
28. Ritonavir: clinical pharmacokinetics and interactions with other anti-HIV agents.
29. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease.
30. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients.
31. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor.
32. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1.
33. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir.
34. Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus.
35. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy.
36. Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy.
37. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease.
38. Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor.
39. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1.
40. Fidelity of HIV-1 reverse transcriptase.
41. Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate.
42. Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors.
43. Human immunodeficiency virus type I viral background plays a major role in development of resistance to protease inhibitors.
44. Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults.
45. Human immunodeficiency virus type 1 protease inhibitors: evaluation of resistance engendered by amino-acid substitutions in the enzyme substrate binding site.
46. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
47. Mutations in retroviral genes associated with drug resistance.
48. Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease.
49. Limited sequence diversity in the HIV type 1 protease gene from clinical isolates and in vivo susceptibility to HIV protease inhibitors.
50. Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment.
51. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo.
52. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites.